- Home
- FT vs ACHV Comparison
FT vs ACHV Comparison
Compare FT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- ACHV
- Stock Information
- Founded
- FT 1988
- ACHV N/A
- Country
- FT United States
- ACHV Canada
- Employees
- FT N/A
- ACHV N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FT Finance
- ACHV Health Care
- Exchange
- FT Nasdaq
- ACHV Nasdaq
- Market Cap
- FT 171.4M
- ACHV 159.0M
- IPO Year
- FT N/A
- ACHV N/A
- Fundamental
- Price
- FT $7.52
- ACHV $4.40
- Analyst Decision
- FT
- ACHV Strong Buy
- Analyst Count
- FT 0
- ACHV 3
- Target Price
- FT N/A
- ACHV $14.00
- AVG Volume (30 Days)
- FT 63.0K
- ACHV 86.3K
- Earning Date
- FT 01-01-0001
- ACHV 11-07-2024
- Dividend Yield
- FT 7.85%
- ACHV N/A
- EPS Growth
- FT N/A
- ACHV N/A
- EPS
- FT N/A
- ACHV N/A
- Revenue
- FT N/A
- ACHV N/A
- Revenue This Year
- FT N/A
- ACHV N/A
- Revenue Next Year
- FT N/A
- ACHV N/A
- P/E Ratio
- FT N/A
- ACHV N/A
- Revenue Growth
- FT N/A
- ACHV N/A
- 52 Week Low
- FT $5.97
- ACHV $3.03
- 52 Week High
- FT $7.23
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- FT 79.00
- ACHV 48.35
- Support Level
- FT $7.31
- ACHV $4.23
- Resistance Level
- FT $7.33
- ACHV $4.64
- Average True Range (ATR)
- FT 0.06
- ACHV 0.17
- MACD
- FT 0.01
- ACHV 0.03
- Stochastic Oscillator
- FT 84.87
- ACHV 55.56
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.